Home Featured Page 158

Featured

Latest

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

atai Life Sciences Announces R&D Day Agenda

Psilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences...

The Art of Microdosing: A Q&A with Dr. James Fadiman Ph.D....

The Interdisciplinary Conference on Psychedelic Research (ICPR)

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety...

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform...

PT365 – Dr. Jennifer Montjoy – KAP: Self-Agency Through Intention, Titration,...

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

atai Life Sciences Announces R&D Day Agenda

Psilera’s Award-Winning Co-Founders To Be Featured Speakers at Upcoming Industry Conferences...

The Art of Microdosing: A Q&A with Dr. James Fadiman Ph.D....

The Interdisciplinary Conference on Psychedelic Research (ICPR)

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial...

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety...

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform...

PT365 – Dr. Jennifer Montjoy – KAP: Self-Agency Through Intention, Titration,...

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY